94109-05-4

The endocannabinoids present a rich system of central cannabinoid (CB₁), peripheral cannabinoid (CB₂), and non-CB receptor-mediated pharmacology that has stimulated research in many fields including memory, weight loss and appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation. Docosanoyl ethanolamide is a saturated N-acylethanolamide. Non-cannabinoid receptor-mediated pharmacology of the saturated ethanolamides is still being elucidated. Other studies indicate they may have a role in the functioning of ion channels.

Docosanoyl Ethanolamide is saturated N-acylethanolamide.

ChEBI: N-(docosanoyl)ethanolamine is an N-(long-chain-acyl)ethanolamine that is the ethanolamide of docosanoic acid. It is a N-(saturated fatty acyl)ethanolamine and a N-(long-chain-acyl)ethanolamine. It is functionally related to a docosanoic acid.

[1] DARREN SMART. ‘Entourage’ effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism[J]. British Journal of Pharmacology, 2009, 136 3: 452-458. DOI: 10.1038/sj.bjp.0704732
[2] MURAT OZ . Effects of saturated long-chain N-acylethanolamines on voltage-dependent Ca2+ fluxes in rabbit T-tubule membranes[J]. Archives of biochemistry and biophysics, 2005, 434 2: Pages 344-351. DOI: 10.1016/j.abb.2004.11.010